With a make-or-break PhIII readout looming, a struggling Concert offloads a 'portfolio' of drugs

In a brief statement out on Friday, a tiny outfit called Terran Biosciences put out word that it has snapped up a group of CNS drugs from Concert Pharmaceuticals, which axed its mid-stage schizophrenia drug a little more than a year ago after a crushing Phase II failure. There’s no word on which drugs are involved and not a peep about the dollars involved.